BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 2111665)

  • 21. Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute myocardial infarction. Preliminary results of a randomised study.
    Monnier P; Sigwart U; Vincent A; Bachmann F; Goy JJ; Schaller MD; Kaufmann U; Badan M; Grbic M; Perret C
    Drugs; 1987; 33 Suppl 3():175-8. PubMed ID: 3315587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reocclusion three months after successful thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activating complex.
    Takens BH; Brügemann J; van der Meer J; den Heijer P; Lie KI
    Am J Cardiol; 1990 Jun; 65(22):1422-4. PubMed ID: 2191581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reperfusion, patency and reocclusion with anistreplase (APSAC) in acute myocardial infarction.
    Anderson JL
    Am J Cardiol; 1989 Jul; 64(2):12A-17A; discussion 24A-26A. PubMed ID: 2662737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary safety and tolerance data obtained in the comparative study of anisoylated plasminogen streptokinase activator complex versus heparin.
    Croydon EA
    Drugs; 1987; 33 Suppl 3():293-6. PubMed ID: 3315611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of intravenous anisoylated plasminogen streptokinase activator complex with intracoronary streptokinase in acute myocardial infarction.
    Bonnier JJ
    Drugs; 1987; 33 Suppl 3():151-3. PubMed ID: 3315583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1.
    O'Connor CM; Meese R; Carney R; Smith J; Conn E; Burks J; Hartman C; Roark S; Shadoff N; Heard M
    J Am Coll Cardiol; 1994 Jan; 23(1):11-8. PubMed ID: 8277068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Study of new thrombolytic agents in myocardial infarction: a multicenter randomized trial (APSAC versus rt-PA)].
    Cassagnes J; Machecourt J; Bassand JP; Lusson JR; Wolf JE; Anguenot T; Maublant J; Fagret D; Cardot JC
    Arch Mal Coeur Vaiss; 1992 Nov; 85(11):1593-9. PubMed ID: 1300957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coronary thrombolysis during acute myocardial infarction by intravenous BRL 26921, a new anisoylated plasminogen-streptokinase activator complex.
    Kasper W; Meinertz T; Wollschläger H; Bonzel T; Wolff P; Drexler H; Hofmann T; Zeiher A; Just H
    Am J Cardiol; 1986 Sep; 58(6):418-21. PubMed ID: 3529908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.
    Kasper W; Meinertz T; Wollschläger H; Bonzel T; Chen C; Hofmann T; Zeiher A; Drexler H; Just H
    Drugs; 1987; 33 Suppl 3():112-6. PubMed ID: 3315575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
    Renkin J; Beys CC; Lavenne-Pardonge E; Pintens H; Col J
    Drugs; 1987; 33 Suppl 3():253-60. PubMed ID: 3315603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiographic assessment of patency and reocclusion: preliminary results of the Dutch APSAC Reocclusion Multicenter Study (ARMS).
    Visser RF
    Clin Cardiol; 1990 Mar; Suppl 5():V45-7; discussion V67-72. PubMed ID: 2182241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.
    Bossaert LL
    Drugs; 1987; 33 Suppl 3():287-92. PubMed ID: 3315610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reperfusion in acute myocardial infarction. A multicentre randomised trial of early intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in the United States.
    Anderson JL
    Drugs; 1987; 33 Suppl 3():154-62. PubMed ID: 3315584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
    Crabbe SJ; Grimm AM; Hopkins LE
    Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison in acute myocardial infarction of anisoylated plasminogen streptokinase activator complex versus heparin evaluated by simultaneous thallium-201/technetium-99m pyrophosphate tomography.
    Krause T; Kasper W; Meinertz T; Schnitzler M; Just H; Schümichen C; Moser E
    Am J Cardiol; 1993 Jan; 71(1):8-13. PubMed ID: 8420241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The APSAC interventional mortality study (AIMS) trial: mortality data.
    Julian DG
    Clin Cardiol; 1990 Mar; Suppl 5():V20-1; discussion V27-32. PubMed ID: 2182236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction.
    Julian DG; Borthwick LS; Reid D; Jennings KP; Wainwright RJ; Rodger JC; Wood D; Phillips WS
    Drugs; 1987; 33 Suppl 3():261-7. PubMed ID: 3315604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
    Anderson JL; Becker LC; Sorensen SG; Karagounis LA; Browne KF; Shah PK; Morris DC; Fintel DJ; Mueller HS; Ross AM
    J Am Coll Cardiol; 1992 Oct; 20(4):753-66. PubMed ID: 1527286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.
    Anderson JL
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):22B-27B. PubMed ID: 3312369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased survival after APSAC: 30-day and 12-month mortality data from the APSAC Intervention Mortality Study.
    Julian DG
    Am J Cardiol; 1989 Jul; 64(2):27A-29A; discussion 41A-42A. PubMed ID: 2662740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.